Antithrombotic materials and methods

Abstract

Antithrombotic materials and methods are provided for the treatment of thrombotic disorders, in which therapeutically effective amounts of BPI protein products are administered.

1 . A method for slowing clot formation in blood comprising administering to a subject a BPI protein product in an amount effective to delay or prevent clot formation in the blood.  
     
     
         2 . A method for enhancing clot dissolution in blood comprising administering to a subject a BPI protein product in an amount, effective to enhance clot dissolution in the blood.  
     
     
         3 . A method for treating a thrombotic disorder in a subject comprising administration of a pharmaceutically effective amount of a BPI protein product.  
     
     
         4 . A method for treating a thrombotic disorder in a subject comprising co-administration of a pharmaceutically effective amount of a BPI protein product and a thrombolytic agent.  
     
     
         5 . The method of  claim 4  wherein the amount of the thrombolytic agent is less than that required for a desired pharmaceutical effect when the thrombolytic agent is administered as a monotherapy.  
     
     
         6 . A method for enhancing reperfusion or reducing reocclusion in a subject treated with a thrombolytic agent comprising co-administration of a pharmaceutically effective amount of a BPI protein product and the thrombolytic agent.  
     
     
         7 . A method for decreasing the dose of a thrombolytic agent required to establish reperfusion or to reduce reocclusion in a subject comprising co-administration of a BPI protein product and a thrombolytic agent, the dosage of the thrombolytic agent being less than that required for a desired pharmaceutical effect when the thrombolytic agent is administered as a monotherapy.  
     
     
         8 . A method of slowing clot formation in blood comprising contacting the blood with an amount of BPI protein product effective to delay or prevent clot formation in the blood.  
     
     
         9 . A method for enhancing clot dissolution in blood comprising contacting the blood with an amount of BPI protein product effective to dissolve or lyse the clot.  
     
     
         10 . The method of claims  1 ,  2 ,  3 ,  4 ,  5 ,  6 ,  7 ,  8  and  9  wherein the BPI protein product is an amino-terminal fragment of BPI protein having a molecular weight of about 21 kD to 25 kD.  
     
     
         11 . The method of claims  1 ,  2 ,  3 ,  4 ,  5 ,  6 ,  7 ,  8  and  9  wherein the BPI protein product is rBPI 23  or a dimeric form thereof.  
     
     
         12 . The method of claims  1 ,  2 ,  3 ,  4 ,  5 ,  6 ,  7 ,  8  and  9  wherein the BPI protein product is rBPI 21 .